David Jj Waugh

List of Publications by Year in Descending Order

50 papers	4,023 citations	30 h-index	54 g-index
54 ext. papers	4,482 ext. citations	7.2 avg, IF	5.38 L-index

#	Paper	IF	Citations
50	Prostate cancer heterogeneity assessment with multi-regional sampling and alignment-free methods. *NAR Genomics and Bioinformatics*, **2020**, 2, lqaa062	3.7	
49	Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. *Cell Reports*, **2019**, 28, 2156-2168.e5	10.6	59
48	ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGA. *Cancer Research*, **2019**, 79, 2072-2075	10.1	2
47	A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases. *Journal of Pathology: Clinical Research*, **2018**, 4, 103-113	5.3	7
46	Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists. *Cell Death and Disease*, **2018**, 9, 1081	9.8	9
45	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. *European Urology*, **2017**, 72, 509-518	10.2	14
44	PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry. *Human Pathology*, **2016**, 47, 95-103	3.7	13
43	PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. *Oncotarget*, **2016**, 7, 7885-98	3.3	25
42	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. *Clinical Cancer Research*, **2016**, 22, 4095-104	12.9	88
41	Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. *Cancer*, **2016**, 122, 664-73	6.4	3
40	CD44 increases the efficiency of distant metastasis of breast cancer. *Oncotarget*, **2015**, 6, 11465-76	3.3	71
39	CD44-mediated activation of 51-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and fibronectin-enriched matrices. *Oncotarget*, **2015**, 6, 36762-73	3.3	31
38	Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. *Oncotarget*, **2014**, 5, 4895-908	3.3	62
37	TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities. *Oncotarget*, **2014**, 5, 1609-20	3.3	28
36	Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner. *Gene*, **2013**, 526, 46-53	3.8	21
35	Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response. *International Journal of Cancer*, **2013**, 132, 1323-32	7.5	30
34	Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. *European Urology*, **2013**, 64, 177-88	10.2	52

33	Reply from Authors re: Zoran Culig. CXCL8, an Underestimated Bad Guy in Prostate Cancer. Eur Urol 2013;64:189–90. *European Urology*, **2013**, 64, 190-192	10.2	
32	Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. *Pharmaceuticals*, **2013**, 6, 929-59	5.2	90
31	Ex vivo expansion of human outgrowth endothelial cells leads to IL-8-mediated replicative senescence and impaired vasoreparative function. *Stem Cells*, **2013**, 31, 1657-68	5.8	43
30	Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. *PLoS ONE*, **2013**, 8, e69604	3.7	86
29	CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. *Breast Cancer Research*, **2012**, 14, R84	8.3	50
28	Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. *Clinical Cancer Research*, **2012**, 18, 3822-33	12.9	43
27	Growth inhibitory activity of extracted material and isolated compounds from the fruits of Kigelia pinnata. *Planta Medica*, **2010**, 76, 1840-6	3.1	18
26	Adhesion and Penetration: Two Sides of CD44 Signal Transduction Cascades in the Context of Cancer Cell Metastasis **2009**, 109-125		1
25	Synthesis and in vitro and in vivo evaluation of a series of dihydroisocoumarin derivatives conjugated with fatty acids, alcohols, and amines as potential anticancer agents. *Bioconjugate Chemistry*, **2009**, 20, 1737-51	6.3	17
24	The interleukin-8 pathway in cancer. *Clinical Cancer Research*, **2008**, 14, 6735-41	12.9	1466
23	Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 327, 746-59	4.7	90
22	Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. *Molecular Cancer Therapeutics*, **2008**, 7, 2649-61	6.1	77
21	Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. *Carcinogenesis*, **2008**, 29, 1148-56	4.6	108
20	Multi-faceted roles for CXC-chemokines in prostate cancer progression. *Frontiers in Bioscience - Landmark*, **2008**, 13, 4595-604	2.8	43
19	HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. *Oncogene*, **2007**, 26, 7333-45	9.2	167
18	Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. *Molecular Cancer Research*, **2007**, 5, 737-48	6.6	84
17	The emerging role of CD44 in regulating skeletal micrometastasis. *Cancer Letters*, **2006**, 237, 1-9	9.9	56
16	Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. *Oncogene*, **2006**, 25, 6079-91	9.2	97

15	Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. *Clinical Cancer Research*, **2005**, 11, 4117-27	12.9	178
14	CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. *Cancer Research*, **2004**, 64, 5702-11	10.1	208
13	Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha 1B-adrenergic receptor. *Journal of Biological Chemistry*, **2001**, 276, 13738-43	5.4	78
12	Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. *Nature Medicine*, **2000**, 6, 1388-94	50.5	115
11	Regulation of the cellular localization and signaling properties of the alpha(1B)- and alpha(1D)-adrenoceptors by agonists and inverse agonists. *Molecular Pharmacology*, **2000**, 57, 659-66	4.3	89
10	Novel aromatic residues in transmembrane domains IV and V involved in agonist binding at alpha(1a)-adrenergic receptors. *Journal of Biological Chemistry*, **2000**, 275, 11698-705	5.4	17
9	Urotensin II in the central nervous system of the frog Rana ridibunda. Biochemical characterization and immunohistochemical localization. *Annals of the New York Academy of Sciences*, **1998**, 839, 506-7	6.5	8
8	The agonism and synergistic potentiation of weak partial agonists by triethylamine in alpha 1-adrenergic receptor activation: evidence for a salt bridge as the initiating process. *Molecular Pharmacology*, **1998**, 53, 766-71	4.3	6
7	Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. *The Journal of Experimental Zoology*, **1996**, 275, 226-238		85
6	Urotensin II in the central nervous system of the frog Rana ridibunda: immunohistochemical localization and biochemical characterization. *Journal of Comparative Neurology*, **1996**, 364, 324-39	3.4	45
5	A peptide from the caudal neurosecretory system of the dogfish Scyliorhinus canicula that is structurally related to urotensin I. *General and Comparative Endocrinology*, **1995**, 99, 333-9	3	19
4	Tachykinins with unusual structural features from a urodele, the amphiuma, an elasmobranch, the hammerhead shark, and an agnathan, the river lamprey. *Peptides*, **1995**, 16, 615-21	3.8	33
3	Novel tachykinins from the brain of the sea lamprey, Petromyzon marinus, and the skate, Raja rhina. *Peptides*, **1994**, 15, 155-61	3.8	27
2	Primary structures and biological activities of substance-P-related peptides from the brain of the dogfish, Scyliorhinus canicula. *FEBS Journal*, **1993**, 214, 469-74		27
1	Purification and characterization of urotensin II from the brain of a teleost (trout, Oncorhynchus mykiss) and an elasmobranch (skate, Raja rhina). *General and Comparative Endocrinology*, **1993**, 92, 419-27	3	36